Leukemia – Page 2 – VJRegenMed

DARIC33 CAR T-cells in AML

DARIC33 CAR T-cells in AML

Jacob Appelbaum • 12 May 2021

Challenges of CAR T-cell therapy for AML: is CD38 the answer?

Challenges of CAR T-cell therapy for AML: is CD38 the answer?

Lei Yu • 3 Jun 2021

Identifying early predictors of neurotoxicity following CAR-T infusion

Identifying early predictors of neurotoxicity following CAR-T infusion

Jaap Boelens • 26 May 2021

Allogenic NKX101 in r/r AML

Allogenic NKX101 in r/r AML

James Trager • 22 Feb 2021

Horizon scanning in anti-CD19 CAR T-cell therapy

Horizon scanning in anti-CD19 CAR T-cell therapy

Marco Alessandrini • 20 May 2021

DARIC33: CAR T with an on/off switch

DARIC33: CAR T with an on/off switch

Jacob Appelbaum • 12 May 2021

Improving education in cell therapy

Improving education in cell therapy

Emanuele Ostuni • 12 Apr 2021

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS

David Gilham • 22 Feb 2021

CAR T-cells in adult ALL

CAR T-cells in adult ALL

Arnon Nagler • 1 Feb 2021

Novel strategies to optimize CAR T-cell therapy

Novel strategies to optimize CAR T-cell therapy

Arnon Nagler • 1 Feb 2021

Infectious complications after CAR T-cell therapy

Infectious complications after CAR T-cell therapy

Joshua Hill • 10 Feb 2021

CAR-T trials to watch in China

CAR-T trials to watch in China

Jianxiang Wang • 2 Feb 2021

Progression of CAR-T trials in China

Progression of CAR-T trials in China

Jianxiang Wang • 2 Feb 2021

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies

Jordan Gauthier • 28 Jan 2021

Infection prevention in patients receiving CAR T-cells

Infection prevention in patients receiving CAR T-cells

Joshua Hill • 10 Feb 2021

CAR-T in myeloma: key players in the therapeutic landscape

CAR-T in myeloma: key players in the therapeutic landscape

Mohamad Mohty • 26 Jan 2021